Post-reactivation humoral immune response with Soberana 01 vaccine in IPK workers, 2022.

Teresa  Lisboa; Licel Rodríguez; Caridad Montalvo; Carmen Viada; Delmis Alvarez; Madelyn Garcés; Margarita Gascón; María Guzmán; Suset Isabel  Oropesa

doi:10.70099/BJ/2025.02.03.11

Authors

Teresa Lisboa Instituto de Medicina Tropical Pedro Kourí (IPK), La Habana, Cuba https://orcid.org/0000-0001-5033-5616
Licel Rodríguez Instituto de Medicina Tropical Pedro Kourí (IPK), La Habana, Cuba https://orcid.org/0000-0002-7742-3146
Caridad Montalvo Instituto de Medicina Tropical Pedro Kourí (IPK), La Habana, Cuba
Carmen Viada Centro de Inmunología Molecular (CIM), La Habana, Cuba https://orcid.org/0000-0002-1604-3545
Delmis Alvarez Instituto de Medicina Tropical Pedro Kourí (IPK), La Habana, Cuba https://orcid.org/0000-0002-0851-4167
Madelyn Garcés Instituto de Medicina Tropical Pedro Kourí (IPK), La Habana, Cuba https://orcid.org/0000-0002-0621-7046
Margarita Gascón Instituto de Medicina Tropical Pedro Kourí (IPK), La Habana, Cuba https://orcid.org/0000-0003-1363-4785
María Guzmán Instituto de Medicina Tropical Pedro Kourí (IPK), La Habana, Cuba https://orcid.org/0000-0003-3927-0844
Suset Isabel Oropesa nstituto de Medicina Tropical Pedro Kourí (IPK), La Habana, Cuba https://orcid.org/0000-0001-5159-3350

DOI:

https://doi.org/10.70099/BJ/2025.02.03.11

Keywords:

COVID-19 booster vaccination, humoral immune response, long-term immunity, vaccine immunogenicity, healthcare workers

Abstract

SARS-CoV-2, the causative agent of COVID-19, was declared a pandemic on March 11, 2020, and due to its high morbidity and mortality rates, it became a global health priority. Cuba developed its vaccines (SOBERANA 01, 02, and Plus), and as part of an intervention study launched in 2021 among healthcare workers, a booster dose was administered in November of that year. This study aimed to evaluate the humoral immune response after the SOBERANA 01 booster in workers at the Pedro Kourí Institute of Tropical Medicine (IPK) and to analyze its association with sociodemographic and clinical-epidemiological variables. A total of 418 whole blood and serum samples were collected one month after the booster, and anti-SARS- CoV-2 antibodies were assessed using a lateral flow immunochromatographic assay and the UMELISA SARS-CoV-2 IgG technique. The rapid assay detected IgG in 95.7% of samples and marginal IgM positivity (0.23%), while UMELISA confirmed IgG in 99.5% of cases. No significant differences were observed according to sociodemographic or clinical characteristics, although a positive association was found between prior COVID-19 infection and rapid test positivity. These findings demonstrate that SOBERANA 01 induces a strong humoral response in healthcare workers, supporting its use in high-risk populations and confirming that Cuban-developed vaccines provide immune protection comparable to internationally recognized platforms.

References

1. Hui DS, Azhar EI, Madani TA, Ntoumi F, Kock R, Dar O, et al. (2020) The Continuing 2019-nCoV Epidemic Threat of Novel Corona Virus to Global Health—The Latest 2019 Novel Corona Virus Outbreak in Wuhan, China. International Journal of Infectious Diseases, 91,264-266. https://doi.org/10.1016/j.ijid.2020.01.009

2. Hung LS. The SARS epidemic in Hong Kong: what lessons have we learned? J R Soc Med [Internet]. Agosto de 2003 [citado 6 de febrero de 2020];96(8):374-8. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC539564/

3. Deng, S.-Q.; Peng, H.-J. Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China. J. Clin. Med. 2020, 9, 575. https://doi.org/10.3390/jcm9020575

4. Cuba divulga el Protocolo de Actuación Nacional para la COVID-19 (MINSAP). Boletín Epidemiológico Semanal: Protocolo de actuación nacional para la covid-19. Infomed: IPK, 2020, 11 de mayo de 2020.

5. Picazo JJ. Vacuna frente al COVID-19. Revista Española de Quimioterapia, ISSN-e 0214-3429, Vol. 34, Nº 6, 2021, págs. 569-598. doi:10.37201/req/085.2021

6. Registro Público Cubano de Ensayos Clínicos. Soberana 02A ,2021 [Disponible en: https://rpcec.sld.cu/en/ensayos/RPCEC00000347Sp. 294. Valdes-Balbin Y, Santana-Mederos D, Quintero L, Fernández S, Rodríguez L, Sánchez Ramírez B, et al. SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies. ACS Chem Biol. 2021;16(7):1223-33. DOI: 10.1021/acschembio.1c00272.

7. Shrotri, M.; Navaratnam, A.M.; Nguyen, V.; Byrne, T.; Geismar, C.; Fragaszy, E.; Beale, S.; Fong, W.L.E.; Patel, P.; Kovar, J. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet 2021, 398, 385–387.

8. Cirillo N. Do healthcare workers need a COVID-19 vaccine booster? DOI: https//doi.org/10.1016/S1473 ̵ 3099(21)00782 www.thelancet.com/infection Vol January 22 2022.

9. Emanuel EJ, Skorton DJ. Mandating COVID-19 Vaccination for Health Care Workers. Ann Intern Med. 2021 Sep;174(9): 1308-1310.doi: 10.7326/M21-3150.

10. Pegu A, O’Connell SE, Schmidt SD, O’Dell S, Talana CA, Lai L, et al. Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants. Science 2021;373(September (6561)):1372–1377,2021.

11. Falsey AR, Frenck RW, Walsh EE, Kitchin N, Absalon J, Gurtman A, et al. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. N Engl J Med 2021 doi:10.1056/NEJMc2113468.

12. Higgins RL, Rawlings SA, Case J, Lee FY, Chan CW, Barrick B, Burguer ZC (2021) Longitudinal SARS-CoV-2 antibody stud using the Easy Check COVID-19 IgM/IgG lateral flow assay. PLoS One.2021 March 4;16(3): e0247797.doi: 10.1371/journal.pone.0247797.

13. Worseley CM, VAN der Mescht MA, Hoffman D, Meyer PWA, Ueckermann V. Rossouw TM. Decline in antibody responses to SARS-CoV-2 post-vaccination poses a risk to health care workers. Doi: https://doi.org/10.1016/j.jinF.2022.06.008.

14. Salvagno GL, Henry Brandon MP, De Nitto S, Gianluca G , Lippi G Pigh L et al Effect of BNT162b2 booster dose on antiSARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals https://doi.org/10.1515/cclm-2022-0212 Received March 8, 2022; accepted March 9, 2022; published online March 18, 2022.

15. Spitzer A, Angel Y, Muradi O, Zeltser D, Hanoch S, Gold E and Goldiner S et al. Association of a Third dose of BNT162b2 Vaccine with Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel 341-349 doi:10.100/jama.2021.23641.

16. Çağlayand D, Sϋner AF, Şiyen N, Guzel I, Irmak G, Çelik M, Ergör A et al. An analysis of antibody response following the second dose CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare works in Turkey J. med virol .2022 My;94(5):2212-2221.doi:101002/Jmv.27620.Epub 202feb3.PMID:35075655;PMC9015267.

17. Skrzat-Klapaczynska, A.; Bienkowski, C.; Kowalska, J.; Paciorek, M.; Puła, J.; Krogulec, D.; Stengiel, J.; Pawełczyk, A.; Perlejewski, K.; Osuch, S.; et al. The Beneficial Effect of the COVID-19 Vaccine Booster Dose among Healthcare Workers in an Infectious Diseases Center. Vaccines 2022, 10, 552. https://doi.org/10.3390/ vaccines10040552.

18. Bartleson.JM., Radenkovich D, Covarrubias AJ, Furman D, Winer D, and Verdin E. Nature Aging,2021 SARS-CoV-2, COVID-19 and the aging immune system. https://doi.org/10.1038/s43587-021-00114-7.

19. Pedreáñez A, Subarán Mosquera J, Muñoz N, Tene D, and Robalino J. The disadvantage of men against COVID-19. Analysis of the influence of sex on the immune response to SARS-CoV-2 infection.doi:10.32457/ijmas. v8i3.1572

20. Zumaeta Villena E, González Griego A, Ramírez Albajes V, and Figueroa Barrios R. Immunogenicity of Cuban recombinant vaccine against hepatitis B IN Peruvian health workers. Rev Cubana Invest Biomed 2000;19(1):43-9)

21. Hibino M, Watanabe S, Kamada R, Tobe S, Maeda K, Horiuchi S, and Kondo T, Antibody Response to the BNT162B2 mRNA vaccine in healthcare workers in hospital in Japan: A comparison of two assays for anti spick protein immunoglobulin G Internacional Medicine the Japanese Society of internal Medicine Doi: https://doi.org/10.2169/Internalmedicine8704-21,

22. Saltoğlu N, Ӧykϋ Dinç H, Balkan I, Can G, Ӧzbey D, Beytur N A, keskin E, et al. Heterologous booster COVID-19 vaccination elicited potent immune responses in HCWs Https://doi.org/10.1016/j.daigmicrobio.2022.115758

23. Soegiarto G, Wulandari L, Purnomosarí D, Dhia Fahmita K, Ikhwan Gautama H, Hadmoko S, Fetarayani D, et al. Hypertension is associated with antibody response and breakthrough infection in Healthcare Workers following vaccination with inactivated SARS-CoV -2. hppts://doi.org/10.1016/j.vaccine.2022.05.059.

24. Hussein K, Dabaja-Younis H, Szwarcwort-Cohen M, Almog R, Leiba R, Weissman A, et al. Immunogenicity and SARS-CoV-2 infection following the fourth BNT162b2 booster dose among Healthcare Workers. Doi 10.3390/vaccines11020283.

25. Pani A, Romandini A, Schianchi A, Senatore M, Gagliardi OM, Gazzanica G, et al. Antibody Response to COVID-19 Booster Vaccination in Healthcare Works. doi.10.3389/fimmu.2022.872667.

26. Brehm TT, Ullrich F, Thompson M, Kuchen J, Schwinge D, Huber S, et al. Tree Separate Spike Antigen Exposures by COVID-19 Vaccination or SARS-CoV-2 infection Elicit Strong humoral immune response in Healthcare Workers https://doi.org/10.3390/vaccines 10071086.

Post-reactivation humoral immune response with Soberana 01 vaccine in IPK workers, 2022.

Authors

DOI:

Keywords:

Abstract

References

Downloads

Published

How to Cite

Issue

Section

Categories

License